JNJ's 60-Year Streak Against AbbVie's Fatter Yield

24/7 Wall St. framed a choice between Johnson & Johnson (NYSE: JNJ), which has raised its dividend for six decades and carries what it calls a fortress balance sheet, and AbbVie Inc (NYSE: ABBV), which pays a higher yield while absorbing the collapse of its blockbuster drug; JNJ traded at $260.99 (+0.46%) and ABBV at $248.40 (-0.68%) as of 18:49 GMT on 12 Aug 2026.

Two of the largest dividend payers in American healthcare are asking income investors the same question in opposite ways. Johnson & Johnson (NYSE: JNJ) offers a payout with six decades of unbroken annual increases behind it and what 24/7 Wall St describes as a fortress balance sheet supporting it. AbbVie Inc (NYSE: ABBV) offers more cash per dollar invested today, while working to replace revenue from a blockbuster drug whose sales are collapsing.

Neither is obviously the wrong answer. But they are not the same trade, and the difference is not the yield gap — it is what has to go right for the dividend to keep growing.

Where the two stocks stand right now

As of the last trade at 18:49 GMT on 12 August 2026, Johnson & Johnson changed hands at $260.99, up 0.46% from the prior close of $259.80, having traded between $255.25 and $261.41 on the session. AbbVie was at $248.40, down 0.68% from $250.09, with a day range of $245.52 to $250.09 — meaning the stock spent the whole session below where it closed the day before.

The broad tape was firmer. SPY, tracking the S&P 500, was at $773.58, up 0.39%. QQQ, tracking the Nasdaq 100, was up 0.96% at $725.32. DIA, tracking the Dow 30, was up 0.13% at $537.98. So JNJ modestly outpaced the Dow and roughly matched the S&P on the day, while AbbVie leaked value against a rising market — a small data point, but the kind that accumulates when a company is being marked on the pace of a transition rather than on last quarter's cash flow.

What a six-decade raise streak actually buys you

A dividend streak that long is not a promise about the future. It is evidence about behavior. To keep an annual increase intact through sixty years, a company has to survive recessions, patent cliffs, litigation, currency shocks and management turnover without ever choosing to trim the payout. That record only exists at firms where the dividend has been treated as a fixed obligation rather than a residual — the last line to be cut, not the first.

Combine that with a balance sheet described as fortress-grade and you get the specific quality income investors are buying at Johnson & Johnson: optionality. A company with low leverage and heavy cash generation can absorb a bad legal outcome or a soft product cycle by borrowing or trimming buybacks rather than by touching the dividend. The streak is durable precisely because there are other levers to pull first.

What you give up is yield. Investors pay a premium for reliability, and a premium price mechanically produces a lower starting yield. That is the trade, stated plainly.

AbbVie's yield is a payment for a specific risk

AbbVie's higher yield is not a gift and it is not a mispricing to be casually harvested. It is compensation for a visible, quantifiable problem: the erosion of a blockbuster franchise that once carried an enormous share of company revenue. Biosimilar competition on a drug of that scale does not chip away at sales — it removes them on a schedule, and pricing pressure typically outruns volume loss.

The bull case is that the replacement portfolio ramps faster than the legacy product falls, so total revenue troughs and then grows again. When that works, an income investor who bought at the higher yield ends up with both the fatter starting payout and a growing one. When it does not work — if new launches undershoot, or the pipeline needs to be supplemented with expensive acquisitions — the dividend has to be funded from a shrinking earnings base, and the cost of that funding is usually debt.

So the honest way to describe AbbVie's dividend is conditional. It is well covered if the transition lands roughly on plan. The yield is high because the market is not certain it will.

The three numbers that settle it

Yield is the least informative figure in this comparison. Three others matter more, and income investors should look them up in the most recent filings rather than accept a summary of them.

• Free cash flow coverage. Not earnings coverage — cash. Dividends are paid from cash, and accounting earnings at large pharmaceutical companies are noisy with amortization, impairments and legal charges. The question is how many times over trailing free cash flow covers the annual cash dividend, and whether that multiple is widening or narrowing.
• Leverage and maturity schedule. A company that has borrowed to buy growth has less room to borrow again. Net debt relative to EBITDA, and when that debt comes due, determines whether a bad year is survivable without touching the payout.
• The replacement ramp. For AbbVie specifically, the growth of newer products against the decline of the legacy blockbuster, quarter by quarter. That crossover is the whole thesis.

How to think about owning one, or both

The framing of safe dividend versus higher yield implies a choice, but for most income portfolios the two assets do different jobs. A payout with a sixty-year record and a strong balance sheet behind it functions as ballast — the position that keeps paying while other holdings are being repaired. A higher-yielding stock in the middle of a product transition functions as a return enhancer, sized accordingly, because the distribution of outcomes is genuinely wider.

The mistake to avoid is treating the two yields as interchangeable and sorting by the bigger number. Screening for yield without asking what the yield is compensating for is how income investors accumulate the very risks they think they are avoiding. A high yield is a market forecast, and the forecast here is specific: revenue from an enormous product is going away, and something must replace it.

What to watch from here

For Johnson & Johnson, the items that could threaten the streak are external rather than operational — large adverse legal outcomes, or a capital allocation decision large enough to strain the balance sheet. Watch the size of any acquisition and how it is funded.

For AbbVie, watch the quarterly split between legacy and newer products, the trajectory of net leverage, and whether the annual dividend increase remains in line with historic practice or slows to conserve cash. A decelerating raise is usually the earliest honest signal a company gives about the strain on its payout — well before any cut is discussed.

Both stocks trade within a few percent of each other in price today, which is coincidence rather than signal. What separates them is the question each one asks of the shareholder: do you want the dividend that has already proven it survives everything, or the one that pays you more to wait and find out?

Key facts

• JNJ price (18:49 GMT, 12 Aug 2026): $260.99, +0.46% (prev close $259.80)
• ABBV price (18:49 GMT, 12 Aug 2026): $248.40, -0.68% (prev close $250.09)
• JNJ dividend record: Six decades of unbroken annual raises
• Market backdrop: S&P 500 (SPY) $773.58, +0.39%; Dow 30 (DIA) $537.98, +0.13%

Frequently asked questions

Which stock has the higher dividend yield, JNJ or AbbVie?

AbbVie offers the higher yield of the two, according to 24/7 Wall St. Johnson & Johnson's lower starting yield reflects the premium investors pay for a payout backed by six decades of unbroken increases and a balance sheet described as fortress-grade. The yield gap is compensation for different risk, not a free upgrade in income.

Why is AbbVie's dividend considered riskier?

AbbVie is absorbing the collapse of a blockbuster drug franchise to biosimilar competition. That removes revenue on a schedule rather than gradually. The dividend remains well covered if newer products ramp fast enough to offset the decline, but if the replacement portfolio undershoots, the payout must be funded from a shrinking earnings base.

How did the two stocks trade on 12 August 2026?

As of the last trade at 18:49 GMT, Johnson & Johnson was at $260.99, up 0.46% from a prior close of $259.80, with a day range of $255.25 to $261.41. AbbVie was at $248.40, down 0.68% from $250.09, trading between $245.52 and $250.09 — entirely below the previous close.

What does a 60-year dividend raise streak prove?

It is evidence about corporate behavior rather than a guarantee. Maintaining annual increases for six decades means the dividend survived recessions, patent expirations, litigation and management changes without being cut. That only happens where the payout is treated as a fixed obligation, with buybacks and borrowing used as shock absorbers first.

Which metrics matter more than yield when comparing the two?

Free cash flow coverage of the annual cash dividend, since dividends are paid in cash and pharmaceutical earnings are distorted by amortization and legal charges. Also net leverage and the debt maturity schedule, which set how much room exists in a bad year. For AbbVie specifically, the quarterly ramp of newer drugs against the legacy decline.

Can an income investor reasonably own both?

Yes, because they serve different roles. A payout with a long unbroken record and low leverage acts as portfolio ballast that keeps paying through drawdowns. A higher-yielding stock in mid-transition acts as a return enhancer and should be sized for a wider range of outcomes. The error is sorting purely by the bigger yield number.

Sources

• Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield — 24/7 Wall St

Photo: Abdul batin · Pexels Licence — source